2. Rohleder, C., Müller, J. K., Lange, B. y Leweke, F. M. (2016) “Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence”, Front Pharmacol. 3. McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A. y Wright, S. (2018) “Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial”, Am J Psychiatry. 4. McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., y Wright, S. (2018) “Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial”, The American journal of psychiatry. 5. Boggs, D. L., Surti, T., Gupta, A., Gupta, S., Niciu, M., Pittman, B., Schnakenberg Martin, A. M., Thurnauer, H., Davies, A., D'Souza, D. C., y Ranganathan, M. (2018) “The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial”, Psychopharmacology. cendeced (depositphotos)
RkJQdWJsaXNoZXIy NTU4MzA1